Search > Macular Degeneration
321 Participants NeededMy employer runs this trial

RO7965032 for Macular Degeneration

Recruiting at 4 trial locations
RS
FR
Overseen ByFastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Genentech, Inc.
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Are You a Good Fit for This Trial?

This trial is for people with geographic atrophy (GA) caused by age-related macular degeneration who have a certain level of vision and clear enough eyes for imaging. Participants must have well-defined GA lesions and meet specific eye health criteria.

Inclusion Criteria

My eyes are healthy enough for clear imaging of the back of my eye.
My vision in the study eye is at least 35 letters on the ETDRS chart at 4 meters.
I have well-defined geographic atrophy in both eyes due to age-related macular degeneration.
See 1 more

Exclusion Criteria

I have a history of repeated eye infections or inflammation.
I do not have proliferative diabetic retinopathy in either eye.
General Exclusion Criteria: History of hypersensitivity, severe allergic reaction or anaphylactic reaction to any component of the investigational drug injection
See 7 more

What Are the Treatments Tested in This Trial?

Interventions

  • RO7965032

Trial Overview

The study compares the effects of an experimental drug, RO7965032, to a placebo in treating vision loss from GA due to AMD. Participants are randomly assigned to receive either the drug or placebo.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Placebo Group

Group I: RO7965032 Dose Level 2Experimental Treatment1 Intervention
Group II: RO7965032 Dose Level 1Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Genentech, Inc.

Lead Sponsor

Trials
1,578
Recruited
569,000+
Ashley Magargee profile image

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

MBA from Harvard University, BA from Princeton University

Levi Garraway profile image

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2021

MD, PhD

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.